A multi-item Physician Global Assessment scale to assess psoriasis disease severity: validation based on four phase III tofacitinib studies

Table 3 Pearson correlation coefficients at the primary assessment time point

Study	Pearson correlation coefficients (Prob > \|r\| under H0: Rho = 0) Number of observations
Study	PGA vs PASI	PGA vs PtGA	PGA vs DLQI
OPT Pivotal 1	0.77 (p < 0.0001) 798	0.70 (p < 0.0001) 790	0.57 (p < 0.0001) 789
OPT Pivotal 2	0.79 (p < 0.0001) 851	0.72 (p < 0.0001) 841	0.53 (p < 0.0001) 843
OPT Compare	0.79 (p < 0.0001) 1027	0.66 (p < 0.0001) 1011	0.53 (p < 0.0001) 1008
OPT Retreatment	0.75 (p < 0.0001) 555	0.70 (p < 0.0001) 549	0.44 (p < 0.0001) 549

DLQI Dermatology Life Quality Index, PASI Psoriasis Area and Severity Index, PGA Physician Global Assessment, PtGA Patient Global Assessment
Italic values represent the number of observations

ISSN: 1471-5945